BACKGROUND AND PURPOSE: To assess whether the pretreatment FDG-PET-defined biologic target volume (PET-BTV) correlates with the anatomical sites of loco-regional failure (LRF) after RT for head and neck cancer (HNC). MATERIALS AND METHODS: We retrospectively identified 61 HNC patients treated definitively with either 3-D CRT or IMRT who had a pre-therapy PET/CT. The GTV and high-risk CTV(1) definitions included composite data obtained from diagnostic CT, PET/CT, physical examination, and MRI when available. The median CTV(1) dose was 70Gy. 95% received chemotherapy. For patients with LRF, a recurrence volume (V(r)) was identified and was mapped to the pretreatment planning CT and pretreatment PET scan. RESULTS: At a median follow-up of 22 months, 15% (9/61) patients had LRF. For patients with a LRF, 100% (9/9) of failures were inside the GTV. One of nine [11% (95% CI: 3-45%)] had V(r) which mapped outside of the pretreatment PET-BTV, while 8/9 patients had V(r) within the PET-BTV. Predictors of LRF in our series included GTV volume (p=0.003), but not mean SUV (p=0.13) or max SUV (p=0.25). CONCLUSIONS: Following treatment in which the GTV was defined based on the composite of imaging and physical examination, the majority, but not all, LRF occurred within the PET-BTV. These results support an important, but not exclusive, role of FDG-PET in defining the GTV.
BACKGROUND AND PURPOSE: To assess whether the pretreatment FDG-PET-defined biologic target volume (PET-BTV) correlates with the anatomical sites of loco-regional failure (LRF) after RT for head and neck cancer (HNC). MATERIALS AND METHODS: We retrospectively identified 61 HNC patients treated definitively with either 3-D CRT or IMRT who had a pre-therapy PET/CT. The GTV and high-risk CTV(1) definitions included composite data obtained from diagnostic CT, PET/CT, physical examination, and MRI when available. The median CTV(1) dose was 70Gy. 95% received chemotherapy. For patients with LRF, a recurrence volume (V(r)) was identified and was mapped to the pretreatment planning CT and pretreatment PET scan. RESULTS: At a median follow-up of 22 months, 15% (9/61) patients had LRF. For patients with a LRF, 100% (9/9) of failures were inside the GTV. One of nine [11% (95% CI: 3-45%)] had V(r) which mapped outside of the pretreatment PET-BTV, while 8/9 patients had V(r) within the PET-BTV. Predictors of LRF in our series included GTV volume (p=0.003), but not mean SUV (p=0.13) or max SUV (p=0.25). CONCLUSIONS: Following treatment in which the GTV was defined based on the composite of imaging and physical examination, the majority, but not all, LRF occurred within the PET-BTV. These results support an important, but not exclusive, role of FDG-PET in defining the GTV.
Authors: C C Ling; J Humm; S Larson; H Amols; Z Fuks; S Leibel; J A Koutcher Journal: Int J Radiat Oncol Biol Phys Date: 2000-06-01 Impact factor: 7.038
Authors: K S Chao; W R Bosch; S Mutic; J S Lewis; F Dehdashti; M A Mintun; J F Dempsey; C A Perez; J A Purdy; M J Welch Journal: Int J Radiat Oncol Biol Phys Date: 2001-03-15 Impact factor: 7.038
Authors: L A Dawson; Y Anzai; L Marsh; M K Martel; A Paulino; J A Ship; A Eisbruch Journal: Int J Radiat Oncol Biol Phys Date: 2000-03-15 Impact factor: 7.038
Authors: Eva Brun; Elisabeth Kjellén; Jan Tennvall; Tomas Ohlsson; Anders Sandell; Roland Perfekt; Roland Perfekt; Johan Wennerberg; Sven Erik Strand Journal: Head Neck Date: 2002-02 Impact factor: 3.147
Authors: K S Clifford Chao; Gokhan Ozyigit; Binh N Tran; Mustafa Cengiz; James F Dempsey; Daniel A Low Journal: Int J Radiat Oncol Biol Phys Date: 2003-02-01 Impact factor: 7.038
Authors: I Frank Ciernik; Elena Dizendorf; Brigitta G Baumert; Beatrice Reiner; Cyrill Burger; J Bernard Davis; Urs M Lütolf; Hans C Steinert; Gustav K Von Schulthess Journal: Int J Radiat Oncol Biol Phys Date: 2003-11-01 Impact factor: 7.038
Authors: Abdallah S R Mohamed; Carlos E Cardenas; Adam S Garden; Musaddiq J Awan; Crosby D Rock; Sarah A Westergaard; G Brandon Gunn; Abdelaziz M Belal; Ahmed G El-Gowily; Stephen Y Lai; David I Rosenthal; Clifton D Fuller; Michalis Aristophanous Journal: Radiother Oncol Date: 2017-07-31 Impact factor: 6.280
Authors: M Picchio; M Kirienko; P Mapelli; I Dell'Oca; E Villa; F Gallivanone; L Gianolli; C Messa; I Castiglioni Journal: Eur J Nucl Med Mol Imaging Date: 2013-08-29 Impact factor: 9.236
Authors: Philippe Lambin; Ruud G P M van Stiphout; Maud H W Starmans; Emmanuel Rios-Velazquez; Georgi Nalbantov; Hugo J W L Aerts; Erik Roelofs; Wouter van Elmpt; Paul C Boutros; Pierluigi Granone; Vincenzo Valentini; Adrian C Begg; Dirk De Ruysscher; Andre Dekker Journal: Nat Rev Clin Oncol Date: 2012-11-20 Impact factor: 66.675
Authors: Anne K Due; Ivan R Vogelius; Marianne C Aznar; Søren M Bentzen; Anne K Berthelsen; Stine S Korreman; Annika Loft; Claus A Kristensen; Lena Specht Journal: Radiother Oncol Date: 2014-06-30 Impact factor: 6.280